(Reuters) – Eli Lilly’s treatment for early Alzheimer’s is expected to be blocked for use by Britain’s National Health Service (NHS), The Telegraph reported on Friday.
The drug donanemab would be rejected by the National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, the newspaper reported citing insiders.
(Reporting by Nilutpal Timsina in Bengaluru)
Comments